Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...
Hosted on MSN1mon
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...
pharmaphorum18d
Gilead tries again with twice-yearly HIV drug lenacapavir
Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
Business Wire25d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral ...
Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...
Benzinga.com23d
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
19.2% of patients on Islatravir-Lenacapavir experienced mild adverse events, like dry mouth and nausea. The data was presented at the ID Week 2024. At 48 weeks, the investigational combination ...
Gilead to present HIV research findings at conference
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
News Medical23d
Affordability and supply remain critical to the success of long-lasting HIV drug
US pharma company Gilead Sciences is seeking regulatory approval for the drug lenacapavir in a number of African countries – a key step towards making it available across the region, where ...
Medical Xpress22d
Success of long-lasting HIV drug hinges on pricing
U.S. pharma company Gilead Sciences is seeking regulatory approval for the drug lenacapavir in a number of African countries—a key step towards making it available across the region, where ...
Nasdaq1mon
Gilead Partners 6 Pharma Cos. To Provide Generic Lenacapavir In High-incidence Countries
Gilead plans to supply lenacapavir to generic manufacturers, priced at no-profit to the company, until they fully support demand. The agreements also cover lenacapavir for HIV prevention that is ...
Morningstar1mon
AHF: Global HIV Response Demands Broader Lenacapavir Access
While AIDS Healthcare Foundation (AHF) welcomed news of Gilead’s expansion of lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with six generic ...
Business Insider24d
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
In this open-label, active-controlled study, virologically suppressed adults on Biktarvy were randomly allocated in a 1:1 ratio to receive either oral islatravir 2 mg and lenacapavir 300 mg once a ...